CT
CRISPR Therapeutics
Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
About
CRISPR Therapeutics is a Swiss-American biotechnology company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines for serious diseases. They develop cures for genetic diseases by precisely modifying DNA, with a diverse portfolio including treatments for hemoglobinopathies, oncology, and regenerative medicine. Their lead program, exagamglogene autotemcel (exa-cel), has received regulatory approval in several countries for sickle cell disease and transfusion-dependent beta thalassemia.
Tags
Company Timeline
Funding rounds, employee growth, revenue, and exits over the same period. News mentions shown as markers.
No timeline data for this period
Score Breakdown
50Traction
40Team
70Visibility
10Profile
0Community
15Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does CRISPR Therapeutics do?
CRISPR Therapeutics is a Swiss-American biotechnology company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines for serious diseases. They develop cures for genetic diseases by precisely modifying DNA, with a diverse portfolio including treatments for hemoglobinopathies, oncology, and regenerative medicine. Their lead program, exagamglogene autotemcel (exa-cel), has received regulatory approval in several countries for sickle cell disease and transfusion-de…
How much funding has CRISPR Therapeutics raised?
CRISPR Therapeutics has raised a total of $547M in funding. The most recent round on record is Series B.
Where is CRISPR Therapeutics headquartered?
CRISPR Therapeutics is headquartered in Zug, Switzerland.
When was CRISPR Therapeutics founded?
CRISPR Therapeutics was founded in 2013.
What industry does CRISPR Therapeutics operate in?
CRISPR Therapeutics operates in Biotechnology, Gene Editing, Therapeutics, Pharmaceuticals.
What is CRISPR Therapeutics's current status?
CRISPR Therapeutics's current operating status is: Public.